Guggenheim Has Lowered Expectations for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM) had its price target decreased by stock analysts at Guggenheim from $95.00 to $60.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 32.68% from the company’s current price.

A number of other equities research analysts have also recently issued reports on TEM. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Wednesday, March 11th. JPMorgan Chase & Co. dropped their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price objective on shares of Tempus AI in a research report on Wednesday, February 25th. HC Wainwright boosted their target price on shares of Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Finally, Robert W. Baird began coverage on shares of Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $75.92.

Tempus AI Price Performance

Shares of TEM opened at $45.22 on Monday. The company has a market cap of $8.08 billion, a P/E ratio of -32.07 and a beta of 5.29. The stock has a fifty day moving average price of $54.12 and a 200 day moving average price of $68.97. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. Tempus AI has a 12 month low of $36.22 and a 12 month high of $104.32.

Insider Activity at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the sale, the chief executive officer directly owned 8,941,533 shares in the company, valued at $586,206,903.48. The trade was a 1.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew Polovin sold 10,949 shares of Tempus AI stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the sale, the executive vice president owned 126,918 shares in the company, valued at approximately $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 568,841 shares of company stock worth $32,579,611 in the last ninety days. 26.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after acquiring an additional 817,014 shares during the period. ARK Investment Management LLC increased its stake in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares during the period. GC Wealth Management RIA LLC bought a new stake in Tempus AI during the fourth quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Tempus AI by 1.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after purchasing an additional 41,728 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its position in Tempus AI by 1.2% in the fourth quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after purchasing an additional 41,728 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Seeking Alpha calls TEM an “attractive entry point” at current prices, framing the pullback as a buying opportunity for investors focused on AI-enabled precision medicine. Tempus AI: An Attractive Entry Point At Current Prices
• Positive Sentiment: Business Insider reports that legendary investors are rotating capital into AI-powered biotech — a sector-level tailwind that benefits TEM given its AI-driven precision medicine positioning. Legendary Investors are Rotating Capital into AI Powered Biotech
• Positive Sentiment: TV/mkt commentator Jim Cramer described Tempus as “a decent spec” and recommended holding some shares rather than selling all — a cautious but overall supportive public endorsement that can bolster retail demand. Jim Cramer on Tempus AI: “It’s a Decent Spec, I Would Hold on to Some, But Not All”
• Neutral Sentiment: Zacks published a comparison of TEM vs. Doximity (DOCS), which is informational for investors evaluating alternatives in medical information systems but doesn’t provide new company-specific catalysts. TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
• Neutral Sentiment: Hims & Hers (HIMS) expanding its personalized digital healthcare platform is a sector development — relevant for competitive context but not an immediate TEM-specific catalyst. Hims & Hers Expands Personalized Digital Healthcare Platform
• Neutral Sentiment: Thermo Fisher’s launch of a next‑gen cryo-TEM is notable for the life‑sciences equipment landscape but is only tangential to Tempus’s software/AI diagnostics business. Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM
• Neutral Sentiment: CNN and other market pages continue to show real‑time quotes and profile data; useful for tracking volatility but not a fresh catalyst. Tempus AI, Inc. Class A
• Negative Sentiment: Guggenheim lowered its price target on TEM from $95 to $60 (still a “buy”), which represents a material downward revision and can weigh on longer‑term upside expectations despite the maintained rating. Benzinga Price Target Report

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.